Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics
Arcus Biosciences, Inc. (RCUS)
Today's Latest Price: $25.47 USD
0.19 (0.75%)
Updated Jul 9 6:40pm
Add RCUS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
RCUS Stock Summary
- For RCUS, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing.
- With a price/sales ratio of 77.6, Arcus Biosciences Inc has a higher such ratio than 97.05% of stocks in our set.
- The volatility of Arcus Biosciences Inc's share price is greater than that of 94.9% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Arcus Biosciences Inc, a group of peers worth examining would be VBLT, ATHX, NTLA, DTIL, and WVE.
- Visit RCUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arcusbio.com.
RCUS Daily Price Range
RCUS 52-Week Price Range
RCUS Stock Price Chart Technical Analysis Charts
RCUS Price/Volume Stats
| Current price | $25.47 | 52-week high | $37.41 |
| Prev. close | $25.28 | 52-week low | $6.30 |
| Day low | $24.74 | Volume | 428,600 |
| Day high | $25.97 | Avg. volume | 610,967 |
| 50-day MA | $28.69 | Dividend yield | N/A |
| 200-day MA | $16.01 | Market Cap | 1.17B |
Arcus Biosciences, Inc. (RCUS) Company Bio
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.
Loading social stream, please wait...